drugset
drugset / Trial / NCT02075281

Effect of LAPS-Exendin on Body Weight in Obese Population

NCT02075281 ↗

Phase 2 Completed 297 enrolled Hanmi Pharmaceutical Company Limited
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the optimal dose and regimen of HM11260C, in combination with a hypocaloric diet, to reduce weight in obese subjects who are otherwise considered in stable health.

Timeline

Start
2014-02
Primary completion
2015-01
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Efpeglenatide Peptide 4 mg Subcutaneous
Subject Efpeglenatide Peptide 6 mg Subcutaneous
Subject Efpeglenatide Peptide 8 mg Subcutaneous

Indications

obesity disorder